[Federal Register Volume 64, Number 118 (Monday, June 21, 1999)]
[Notices]
[Pages 33103-33104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-15639]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by contacting Susan S.
Rucker, J.D., at the Office of Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland
20852-3804; telephone: 301/496-7056 ext. 245; fax: 301/402-0220; e-
mail: sr156v@nih.gov. A signed Confidential Disclosure Agreement will
be required to receive copies of the patent applications.
Transgenomic Viruses
WJ Ramsey, RM Blaese, KG Xanthopoulos (NHGRI)
Serial No. 09/058,686 filed April 10, 1998, PCT/US98/07166 filed April
9, 1998 and 60/043,667 filed April 11, 1997.
Licensing Contact: Susan S. Rucker, 301/496-7056 ext 245
The technology described and claimed in these applications relates
to the fields of gene therapy, the production of transgenic non-human
animals and diagnostic or quality control applications where
identification of an unknown viral genome is desired. More,
particularly the technology described and claimed in the application
relates to chimeric viruses. When used for gene therapy or the
production of transgenic non-human animals the chimeric viruses are
capable of producing secondary virus in a producer cell. The secondary
virus may be any virus other than the primary virus or a Dependovirus.
When used for diagnostic or quality control applications the chimeric
virus complements, in trans, the secondary packaging components found
in the producer cells.
When employed in the fields of gene therapy and the production of
transgenic non-human animals the chimeric virus offers the advantages
of high transduction efficiency, high viral titer, and the ability to
have a producer cell which is from the same source as the target cell
allowing for the production of autologous secondary viruses which evade
the immune response. The chimeric virus is exemplified by an adenovirus
which contains a retroviral vector containing a heterologous protein/
transgene. Other chimeric viruses are adenovirus-togavirus chimera such
as adenovirus-Semiliki Forest virus or adenovirus-Sindbis virus.
[[Page 33104]]
When employed for diagnostic or quality control purposes the
chimeric primary virus is constructed to encode all of the packaging
components necessary to rescue and package a viral genome. The chimeric
primary virus is then used to infect a host cell which is suspected of
containing an unknown or known virus which contains a packaging signal
which can be recognized by the primary chimeric virus.
This research has been published, in part, in Biochem Biophys Res
Commun 246(3): 912-19 (May 29, 1998) and in Gene Therapy 6(3): 454-459
(March 1999).
Dated: June 10, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 99-15639 Filed 6-18-99; 8:45 am]
BILLING CODE 4140-01-M
